SEC Form 4 · accession 0001209191-17-057054
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Raab
Director
Period of report
Oct 12, 2017
Accepted (ET)
Oct 16, 2017 · 9:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 12, 2017 | M | 10,000 | $14.2534 | A | 15,814 | D | |
| Common StockF3 | Oct 12, 2017 | S | 10,000 | $14.2534 | D | 5,814 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $10.53 | Oct 12, 2017 | M | 5,000 | D | Jun 10, 2009 | Jun 10, 2018 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (right to buy) | $7.15 | Oct 12, 2017 | M | 5,000 | D | Jun 10, 2010 | Jun 10, 2019 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
- F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.08 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.08 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.